OM Group

OM Pharma is a global Swiss-based biopharmaceutical company specializing in the development and manufacture of immunotherapeutics derived from bacterial lysates. The company is a pioneer in the field of immunomodulation, with a focus on preventing and treating respiratory and urinary tract infections by stimulating the body's innate and adaptive immune systems. Its flagship products, Broncho-Vaxom and Uro-Vaxom, are marketed in over 100 countries and are increasingly being investigated for broader applications in respiratory diseases like asthma and COPD. Following its 2020 carve-out from Vifor Pharma and acquisition by a group of investors led by Etienne Jornod, OM Pharma has transitioned into an independent entity with a renewed focus on R&D and international expansion.